Sascha Schuermann/Getty Images News
Qiagen NV (NYSE:QGEN) is evaluating the sale of a minority stake in its bioinformatics division, which could value the business at more than $1 billion.
The diagnostic company is working with an advisor to figure out the possibility Buyers of bioinformatics analysis software manufacturers, according to a Bloomberg report from Friday, which quotes familiar people. Negotiations went smoothly and no final decision was made.
According to the report, the share sale is expected to attract interest from private equity firms. In any case, Qiagen (QGEN) is expected to retain a majority interest in the business.
The report is given in the form of Qiagen (QGEN) has been the subject of much M&A talk in recent years, most recently an October report by the WSJ that diagnostics company Bio-Rad Laboratories (BIOLOGICAL) was in Negotiate with competitor Qiagen to incorporate. Bloomberg reported in November 2021 that Qiagen (QGEN) has attracted acquisition interest from French diagnostic company bioMériex. Heat Fisherman (TMO) in 2020 walk away from its acquisition proposal of Qiagen after its holders turned down a sweet offer.
Earlier this month Qiagen (QGEN) indicates completion of DNA collection-Biometrics company Verogen for $150 million.
The base period (QGEN) is scheduled to report Q4 results on February 7. Bio-Rad is expected to report Results on February 16th.
